End-Stage Kidney Disease Clinical Trial
— PEDALOfficial title:
Evaluating the Clinical and Cost-effectiveness of Intra-dialytic Exercise for the Improvement of Health-related Quality of Life in People With Stage 5 Chronic Kidney Disease Undergoing Maintenance Haemodialysis Renal Replacement Therapy.
Verified date | February 2020 |
Source | King's College Hospital NHS Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The PEDAL study aims to evaluate the effectiveness of a 9-month intradialytic exercise
training intervention designed to improve quality of life (QOL) and alleviate functional
limitations in patients with stage 5 Chronic Kidney Disease (CKD) who are on haemodialysis.
Exercise rehabilitation will be compared against established treatment options available
within UK NHS haemodialysis (HD) units. A qualitative substudy will also investigate the
experience and acceptability of the intervention for both participants and members of the
renal care team. In addition, we want to examine whether this type of additional exercise
treatment is cost effective within the health service setting.
PEDAL is designed as a multi centre randomised clinical trial (RCT) and will recruit 380
adult patients who have been on HD for at least 3 months, from 10 HD sites located in
Scotland, England and Wales. The type of exercise programming will consist of cycling
exercise performed during each dialysis session plus a muscle conditioning programme
performed twice per week. All exercise sessions will be supervised by a physiotherapy
assistant. The exercise prescription will be individualised for all patients on the basis of
their fitness and clinical status.
The main objective is to examine the impact of exercise rehabilitation on quality of life and
well being of patients. We hypothesise that the exercise training delivered during
haemodialysis treatment will significantly improve the functional limitations/abilities of
the patients leading to the detection of clinically beneficial improvement in quality of life
outcome, as measured by the KDQOL-36 physical composite score (PCS) at the primary end point.
Status | Completed |
Enrollment | 335 |
Est. completion date | December 2019 |
Est. primary completion date | December 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility |
Inclusion Criteria: 1. Prevalent Stage 5 CKD patients (GFR <15 mL/min) receiving maintenance haemodialysis therapy for more than 3 months 2. Male or female 3. Aged >18 years 4. Able to provide written informed consent Exclusion Criteria: 1. Patients unlikely to be on HD for > 6 months - (this includes cachectic patients, those with severe heart failure, patients in whom dialysis withdrawal is being considered, and patients likely to receive a live-donor transplant or transfer to PD in that period of time); 2. Less than 3 months after the initiation of haemodialysis (patients in this time-frame are generally less clinically stable, many having vascular access procedures performed, and rates of inter-current events, including death and hospitalisation, are very much higher in the first 3 months after commencement of chronic haemodialysis); 3. Deemed to be clinically unstable by treating physician; 4. Dementia or severe cognitive impairment (as will be unable to give consent and/or complete questionnaire assessments); 5. Severe psychiatric disorders - except treated stable |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Kings College Hospital | London |
Lead Sponsor | Collaborator |
---|---|
King's College Hospital NHS Trust | National Institute for Health Research, United Kingdom |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from basline in quality of life on the Kidney Disease QOL questionnaire Physical Composite Score (KDQOL-PCS) at month 6. | The KDQOL is a disease-specific quality of life measure. | Baseline, 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
Active, not recruiting |
NCT05027074 -
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
|
Phase 2 | |
Completed |
NCT03582592 -
Fluid Distribution Timetable on Adherence to Fluid Restriction of Patients With End-Stage Renal Disease on Hemodialysis
|
N/A | |
Completed |
NCT02694068 -
Biological Determinants of Peritoneal Dialysis
|
||
Not yet recruiting |
NCT02832505 -
Applications of MRI in Kidney Disease
|
||
Not yet recruiting |
NCT02590081 -
Effect of Sodium Rinsing Fluid on Blood Pressure and Interdialytic Weight Change in Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT01859884 -
Optimizing Kidney Transplant Informed Consent
|
N/A | |
Completed |
NCT00509236 -
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)
|
Phase 3 | |
Completed |
NCT02009514 -
Glucose Containing and Glucose Free Hemodialysate in Type 2 Diabetic Patients
|
Phase 4 | |
Not yet recruiting |
NCT06377293 -
Effect of Dialysis-specific Therapeutic Diet on Biochemical Parameters in Dialysis Patients
|
N/A | |
Completed |
NCT01528800 -
Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients
|
Phase 2 | |
Completed |
NCT01863914 -
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula
|
Phase 2 | |
Withdrawn |
NCT06030050 -
Animal Assisted Intervention for Hemodialysis Outpatients
|
N/A | |
Completed |
NCT04610593 -
Effects of a Mindfulness-based Intervention in Stress, Pain and Quality of Life in People Undergoing Hemodialysis
|
N/A | |
Recruiting |
NCT05931276 -
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
|
Phase 3 | |
Completed |
NCT00143741 -
Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers
|
Phase 1 | |
Active, not recruiting |
NCT02755610 -
Check List to Improve Patient Self-care and Product Defect Report in Continuous Ambulatory Peritoneal Dialysis
|
N/A | |
Recruiting |
NCT03142529 -
Traditional Chinese Medicine (TCM) Colon Dialysis Treats Non-dialysis End-Stage Kidney Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02342119 -
Increasing Equity in Transplant Evaluation and Living Donor Kidney Transplantation
|
N/A | |
Recruiting |
NCT05614115 -
Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD
|
Phase 1 |